Literature DB >> 23838136

Membranous ABCG2 expression in colorectal cancer independently correlates with shortened patient survival.

Xinying Wang1, Bingqing Xia, Yan Liang, Liang Peng, Zhongqiu Wang, Jingwei Zhuo, Weifei Wang, Bo Jiang.   

Abstract

BACKGROUND: ABCG2 is a member of the ATP binding cassette (ABC) transporter superfamily and identified to play an important role in multidrug resistance in many studies. But the expression of ABCG2 is controversial in many kinds of tumors including colorectal cancer (CRC).
OBJECTIVE: To clarify the expression patterns of ABCG2 and elucidate the prognostic value of ABCG2 in CRC.
METHODS: ABCG2 expression was analyzed in 225 primary CRC tissues using immunohistochemical assessment. Cytoplasmic and membranous immunoreactivity were semiquantitatively scored and correlated with clinicopathological variables. 69 cases were used for survival analysis. χ2 test for trends, Kaplan-Meier analysis and Cox's regression were used for statistical analysis.
RESULTS: 83.1% cases showed positive cytoplasmic expression including 13.3% strongly positive. 66.2% showed positive membranous expression including 15.6% strongly positive. 50% normal mucosa exhibited a strong membranous staining on the apical membrane. The strongly membranous staining significantly correlated to lymph node and distant metastasis. While the cytoplasmic expression levels of ABCG2 protein were only correlated with tumor stage. Survival analysis showed strongly membranous ABCG2 staining correlated to shortened patient survival than negative one (HR=2.439, 95%CI 1.053-5.650, P=0.038), but not cytoplasmic ABCG2 staining. DISCUSSION: Our results showed that membranous ABCG2 expression was significantly associated with Dukes' stage, lymph node metastasis and distant metastasis. However, cytoplasmic ABCG2 expression was only significantly associated with Dukes' stage.
CONCLUSIONS: Strong membranous ABCG2 staining is a potential new independent prognostic factor of CRC. Further studies are needed to clarify the role of ABCG2 in colon carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23838136     DOI: 10.3233/CBM-130344

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  13 in total

1.  Prognostic impact of membranous ATP-binding cassette Sub-family G member 2 expression in patients with colorectal carcinoma after surgical resection.

Authors:  Donghoon Kang; Jae Myung Park; Chan Kwon Jung; Bo-In Lee; Seong Taek Oh; Myung-Gyu Choi
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

2.  The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma.

Authors:  Yuan Yuan; Zhulin Yang; Xiongying Miao; Daiqiang Li; Ziru Liu; Qiong Zou
Journal:  Tumour Biol       Date:  2015-07-16

3.  Mucinous and non-mucinous colorectal cancers show differential expression of chemotherapy metabolism and resistance genes.

Authors:  J P Burke; J H M Prehn; E O'Connell; I S Reynolds; M Salvucci; D A McNamara
Journal:  Pharmacogenomics J       Date:  2021-03-17       Impact factor: 3.550

4.  Enhanced efficacy of photodynamic therapy by inhibiting ABCG2 in colon cancers.

Authors:  Ju Hee Kim; Jae Myung Park; Yoon Jin Roh; In-Wook Kim; Tayyaba Hasan; Myung-Gyu Choi
Journal:  BMC Cancer       Date:  2015-07-07       Impact factor: 4.430

5.  Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.

Authors:  Luodan Zhao; Yuexin Ren; Haikuo Tang; Wei Wang; Qianting He; Jingjing Sun; Xiaofeng Zhou; Anxun Wang
Journal:  Oncotarget       Date:  2015-12-29

6.  Short-term spheroid culture of primary colorectal cancer cells as an in vitro model for personalizing cancer medicine.

Authors:  Maria Jeppesen; Grith Hagel; Anders Glenthoj; Ben Vainer; Per Ibsen; Henrik Harling; Ole Thastrup; Lars N Jørgensen; Jacob Thastrup
Journal:  PLoS One       Date:  2017-09-06       Impact factor: 3.240

7.  ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer.

Authors:  Jesper Andreas Palshof; Camilla Natasha Cederbye; Estrid Vilma Solyom Høgdall; Tim Svenstrup Poulsen; Dorte Linnemann; Sune Boris Nygaard; Jan Stenvang; Ib Jarle Christensen; Benny Vittrup Jensen; Per Pfeiffer; Nils Brünner; Mette Yilmaz; Birgitte Martine Viuff; Dorte Lisbet Nielsen
Journal:  Int J Mol Sci       Date:  2020-07-16       Impact factor: 5.923

8.  CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.

Authors:  Nicola Silvestris; Giovanni Simone; Giulia Partipilo; Emanuela Scarpi; Vito Lorusso; Anna Elisabetta Brunetti; Evaristo Maiello; Angelo Paradiso; Anita Mangia
Journal:  Int J Mol Sci       Date:  2014-09-05       Impact factor: 5.923

9.  Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue.

Authors:  Camilla Natasha Cederbye; Jesper Andreas Palshof; Tine Plato Hansen; Anne Katrine Duun-Henriksen; Dorte Linnemann; Jan Stenvang; Dorte Lisbet Nielsen; Nils Brünner; Birgitte Martine Viuff
Journal:  Sci Rep       Date:  2016-06-03       Impact factor: 4.379

Review 10.  Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review.

Authors:  Dorte Lisbet Nielsen; Jesper Andreas Palshof; Nils Brünner; Jan Stenvang; Birgitte Martine Viuff
Journal:  Int J Mol Sci       Date:  2017-09-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.